SMITH & NEPHEW PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,012 GBX | -0.76% |
|
-0.45% | -5.85% |
| Sales 2024 * | 5.82B 457B | Sales 2025 * | 6.12B 481B | Capitalization | 11.3B 888B |
|---|---|---|---|---|---|
| Net income 2024 * | 541M 42.5B | Net income 2025 * | 694M 54.52B | EV / Sales 2024 * | 2.38 x |
| Net Debt 2024 * | 2.56B 201B | Net Debt 2025 * | 2.23B 175B | EV / Sales 2025 * | 2.21 x |
| P/E ratio 2024 * |
22
x | P/E ratio 2025 * |
16.8
x | Employees | 18,452 |
| Yield 2024 * |
2.95% | Yield 2025 * |
3.31% | Free-Float | 99.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Smith & Nephew Plc
More recommendations
More press releases
More news
| 1 day | -0.76% | ||
| 1 week | -0.45% | ||
| Current month | +3.72% | ||
| 1 month | +4.17% | ||
| 3 months | -10.73% | ||
| 6 months | -1.60% | ||
| Current year | -5.85% |
1 week
1 008.00
1 033.50
1 month
960.601 033.50
Current year
946.001 181.50
1 year
887.001 284.00
3 years
887.001 601.50
5 years
887.002 023.00
10 years
881.002 023.00
| Managers | Title | Age | Since |
|---|---|---|---|
Deepak Nath
CEO | Chief Executive Officer | - | 31/03/22 |
John Rogers
DFI | Director of Finance/CFO | 56 | 11-30 |
Alison Parkes
CMP | Compliance Officer | - | 31/03/99 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marc E. Owen
BRD | Director/Board Member | 65 | 30/09/17 |
Jeremy Maiden
BRD | Director/Board Member | 62 | 13/09/23 |
Rupert Soames
CHM | Chairman | 63 | 25/04/23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.16% | 14 M€ | -3.79% | ||
| 0.52% | 11 M€ | +0.83% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/05/24 | 1,013 | -0.64% | 734 260 |
| 21/05/24 | 1,020 | -0.34% | 1,540,881 |
| 20/05/24 | 1,023 | -0.05% | 1,723,877 |
| 17/05/24 | 1,024 | -0.15% | 2,425,623 |
| 16/05/24 | 1,025 | +0.49% | 1,647,107 |
Delayed Quote London S.E., May 22, 2024 at 03:36 pm
More quotes
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows:
- orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders);
- sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.;
- wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc.
The United States accounts for 53.7% of net sales.
Calendar
24/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
12.96
USD
Average target price
16.36
USD
Spread / Average Target
+26.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.85% | 11.3B | |
| +11.49% | 126B | |
| +4.83% | 9.16B | |
| +37.64% | 5.46B | |
| +8.73% | 3.45B | |
| -10.35% | 2.76B | |
| -10.68% | 2.09B | |
| -10.77% | 2B | |
| -23.65% | 1.77B | |
| -9.29% | 1.12B |
- Stock Market
- Equities
- SN. Stock
